Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
ACADIA Pharmaceuticals Inc.'s quarterly P/E stands at 278.3x, up 637.1% year-over-year — indicating the stock has re-rated higher or earnings have softened.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 9.85 | 278.25 | — | 12.70 | 33.70 | 37.75 | 5.33 | 19.23 | 20.31 | 46.22 | 27.96 | — | 880.51 |
| — | +637.1% | — | -33.9% | +65.9% | -18.3% | -80.9% | — | -97.7% | — | — | — | — | |
| P/S Ratio | 3.61 | 3.59 | — | 3.27 | 3.44 | 2.85 | 2.94 | 2.55 | 2.79 | 3.74 | 5.64 | 4.04 | 5.98 |
| — | +25.8% | — | +28.0% | +23.2% | -23.8% | -47.9% | -36.9% | -53.3% | -41.9% | +19.4% | -20.2% | +41.3% | |
| P/B Ratio | 3.15 | 3.08 | — | 3.97 | 4.42 | 3.64 | 4.17 | 4.43 | 5.23 | 6.64 | 12.07 | 9.45 | 9.99 |
| — | -15.4% | — | -10.3% | -15.3% | -45.2% | -65.5% | -53.1% | -47.7% | -18.6% | +87.5% | +51.9% | +90.7% | |
| P/FCF | 36.74 | 33.41 | — | 12.32 | 5.60 | — | 19.11 | 10.11 | 26.99 | 26.49 | 15.26 | — | 120.50 |
| — | — | — | +21.8% | -79.3% | — | +25.2% | — | -77.6% | — | — | — | — | |
| EV / EBITDA | 26.91 | — | — | 22.21 | 24.36 | 29.49 | 4.39 | 19.36 | 19.55 | 35.39 | 34.73 | — | 203.19 |
| — | — | — | +14.7% | +24.6% | -16.7% | -87.4% | — | -90.4% | — | — | — | — | |
| EV / EBIT | 35.66 | — | — | 19.28 | 26.57 | 34.00 | 99.64 | 19.36 | 21.20 | 48.25 | 36.36 | — | 321.35 |
| — | — | — | -0.4% | +25.4% | -29.5% | +174.1% | — | -93.4% | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
ACADIA Pharmaceuticals Inc.'s operating margin was -1.7% in Q1 2026, down 7.8 pp QoQ and down 9.6 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 7.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.7% | 90.8% | 90.8% | 92.2% | 92.2% | 91.7% | 91.6% | 92.5% | 92.5% | 88.8% | 92.3% | 93.1% | 95.5% |
| — | -1.0% | -0.9% | -0.3% | -0.3% | +3.2% | -0.7% | -0.7% | -3.2% | -9.9% | -6.1% | -5.4% | -2.6% | |
| Operating Margin | 9.8% | -1.7% | 6.1% | 12.8% | 12.2% | 7.9% | 59.1% | 12.6% | 12.6% | 7.4% | 15.1% | -27.3% | 1.8% |
| — | -121.8% | -89.6% | +1.5% | -2.7% | +6.8% | +291.0% | +146.3% | +584.4% | +116.3% | +144.8% | -15.6% | +107.3% | |
| Net Margin | 36.5% | 1.4% | 96.3% | 25.8% | 10.1% | 7.8% | 55.4% | 13.1% | 13.8% | 8.0% | 19.8% | -30.8% | 0.7% |
| — | -82.5% | +74.0% | +96.9% | -27.0% | -3.4% | +179.3% | +142.5% | +1946.8% | +122.1% | +164.8% | -48.0% | +102.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 39.9% | 0.3% | 25.5% | 8.3% | 3.4% | 2.5% | 21.9% | 6.0% | 6.8% | 3.7% | 11.5% | -17.2% | 0.3% |
| — | -88.4% | +16.2% | +37.8% | -50.7% | -31.4% | +90.2% | +134.8% | +2253.6% | +133.3% | +214.2% | -172.2% | +103.7% | |
| ROA | 28.4% | 0.2% | 18.9% | 5.6% | 2.3% | 1.6% | 13.3% | 3.5% | 3.8% | 2.1% | 6.6% | -10.2% | 0.2% |
| — | -86.0% | +42.3% | +62.1% | -40.1% | -20.7% | +100.3% | +133.9% | +2099.6% | +129.8% | +194.6% | -128.5% | +103.1% | |
| ROIC | 10.0% | -0.5% | 1.4% | 4.0% | 4.0% | 2.7% | 24.6% | 5.5% | 6.4% | 3.7% | 8.4% | -13.0% | 0.9% |
| — | -116.6% | -94.2% | -26.7% | -38.0% | -26.5% | +191.5% | +142.1% | +586.7% | +122.5% | +183.2% | -94.1% | +112.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 24.6% YoY to 3.59x, strengthening the short-term liquidity position. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.03 | 0.04 | 0.06 | 0.07 | 0.07 | 0.07 | 0.09 | 0.11 | 0.13 | 0.13 | 0.16 | 0.15 |
| — | -57.3% | -40.1% | -30.1% | -38.7% | -43.1% | -46.4% | -45.8% | -24.9% | -20.6% | -14.4% | +6.6% | +1.5% | |
| Debt / EBITDA | 0.38 | — | 1.98 | 1.42 | 1.59 | 2.52 | 0.33 | 1.56 | 1.75 | 2.88 | 1.56 | — | 12.25 |
| — | — | +505.3% | -9.2% | -8.7% | -12.4% | -79.1% | — | -85.7% | — | — | — | — | |
| Current Ratio | 3.83 | 3.59 | 3.83 | 3.02 | 2.91 | 2.88 | 2.38 | 2.29 | 2.16 | 2.04 | 2.42 | 2.38 | 2.62 |
| — | +24.6% | +61.3% | +31.7% | +34.9% | +40.9% | -1.9% | -3.8% | -17.7% | -8.9% | -40.1% | -46.8% | -42.1% | |
| Quick Ratio | 3.71 | 3.48 | 3.71 | 2.94 | 2.83 | 2.80 | 2.32 | 2.11 | 1.95 | 1.86 | 2.28 | 2.28 | 2.57 |
| — | +24.3% | +59.8% | +38.9% | +45.5% | +51.1% | +1.7% | -7.4% | -24.4% | -16.2% | -42.8% | -48.4% | -42.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ACAD stock.
ACADIA Pharmaceuticals Inc.'s current P/E is 9.9x. The average P/E over the last 3 quarters is 108.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ACADIA Pharmaceuticals Inc.'s current operating margin is 9.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ACADIA Pharmaceuticals Inc.'s business trajectory between earnings reports.